Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

NCT01504776 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Panobinostat
DRUG: Bortezomib

Sponsor

Anand Jillella

Collaborators

[object Object]